Department of Medicine, Metabolic Bone Diseases Unit, Division of Endocrinology, College of Physicians & Surgeons, Columbia University, 630 W. 168th St., PH8W-864, New York, NY, 10032, USA.
Unit of Endocrinology and Diabetes, University Campus Bio-Medico, Rome, Italy.
Osteoporos Int. 2020 Feb;31(2):327-333. doi: 10.1007/s00198-019-05177-2. Epub 2019 Nov 13.
PTH levels might be associated with bone material strength as measured by impact microindentation. Resistance to microfracture is decreased in hypoparathyroidism and appears to be associated with more severe disease and to improve with PTH replacement.
PTH is a key regulator of bone structure and remodeling. When PTH is absent in hypoparathyroidism (HypoPT), bone mass is increased and remodeling is decreased. In addition to bone structure and remodeling, bone material properties contribute to fracture resistance. Yet little is known about the relationship between PTH and bone material properties. Impact microindentation provides a clinical assessment of microfracture resistance, measured as the bone material strength index (BMSi).
Case-control cross-sectional study of PTH levels and in vivo BMSi measurement by impact microindentation at the anterior tibia in HypoPT patients (n = 17) and in controls matched for age, sex, and menopausal status (n = 17), with follow-up in a subgroup of HypoPT patients (n = 5) after recombinant human parathyroid hormone (1-84) [rhPTH(1-84)] treatment.
BMSi was positively associated with PTH levels in controls (r = 0.58, p = 0.02) and was 11% lower (p = 0.01) in HypoPT patients as compared with controls. In HypoPT, lower BMSi was associated with a trend toward greater supplemental calcium doses (p = 0.07). BMSi increased after rhPTH(1-84) treatment in the HypoPT patients who underwent repeat microindentation.
PTH levels might be associated with bone material strength, although other factors might be contributory. In HypoPT, resistance to microfracture is decreased and may be associated with greater supplemental calcium doses and might increase with PTH replacement. It remains to be determined whether changes in bone remodeling and microarchitecture contribute to the effects of PTH on microfracture resistance.
甲状旁腺激素(PTH)水平可能与冲击微压痕测量的骨材料强度有关。在甲状旁腺功能减退症(HypoPT)中,微骨折阻力降低,且似乎与更严重的疾病相关,并随着 PTH 替代治疗而改善。
PTH 是骨结构和重塑的关键调节剂。当 HypoPT 中缺乏 PTH 时,骨量增加,重塑减少。除了骨结构和重塑外,骨材料特性也有助于抗骨折能力。然而,关于 PTH 与骨材料特性之间的关系知之甚少。冲击微压痕提供了对微骨折阻力的临床评估,其表现为骨材料强度指数(BMSi)。
对 HypoPT 患者(n=17)和年龄、性别和绝经状态相匹配的对照组(n=17)的胫骨前冲击微压痕测量的 PTH 水平和体内 BMSi 进行病例对照横断面研究,并对 HypoPT 患者(n=5)进行了亚组随访 rhPTH(1-84)[rhPTH(1-84)]治疗后。
BMSi 与对照组的 PTH 水平呈正相关(r=0.58,p=0.02),而 HypoPT 患者的 BMSi 则比对照组低 11%(p=0.01)。在 HypoPT 中,较低的 BMSi 与补充钙剂量呈增加趋势(p=0.07)。在接受重复微压痕检查的 HypoPT 患者中,rhPTH(1-84)治疗后 BMSi 增加。
PTH 水平可能与骨材料强度有关,但也可能有其他因素。在 HypoPT 中,微骨折阻力降低,可能与补充钙剂量增加有关,并可能随着 PTH 替代治疗而增加。尚需确定骨重塑和微结构变化是否对 PTH 对抗微骨折阻力的作用有影响。